Charles Buck

Chief Innovation Officer at BioAnalysis, LLC

Charles Buck has had a diverse range of experience in the fields of biophysics and biomedicine. charles currently serves as the Chief Innovation Officer at BioAnalysis, LLC, where they focus on identifying new offerings and customers while providing management and mentorship to a growing team. Prior to this, they worked as the Associate Director of Academic Alliances at Exact Sciences, where they established and nurtured partnerships to support development projects. charles also held the position of Center Executive Officer and Associate Vice President at the University of Idaho Coeur d'Alene, where they built strategic partnerships to improve capacity and community impact. Earlier in their career, they served as the Director of Operations at the Bindley Bioscience Center at Purdue University Discovery Park, overseeing projects and managing day-to-day operations. charles also founded a company called Oridis Biomed, where they utilized human tissue archives for drug target discovery and launched a tissue microarray product line. Charles began their career as an Assistant Professor at Emory University.

Charles Buck obtained their Doctor of Philosophy (PhD) degree in Molecular Neurobiology from Cornell University, a program they pursued from 1983 to 1988.

Location

Philadelphia, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


BioAnalysis, LLC

1 followers

A small, agile CRO. The primary function of the scientists at BioAnalysis, LLC is to provide a collaborative workspace that enables productive and effective solutions to the client’s problems. The traditional CRO model works well, however, at BioAnalysis, LLC we believe that collaborative interactions, communication and robust experimental design along with gold-standard quality results are the true value-added. The scientists of BioAnalysis, LLC possess a wealth of experience in characterization of therapeutic proteins, mAbs, and ADC (DARs), non-biologics (Polymers, PEO/PLA, nanoparticles), ICH/FDA regulatory applications, process development, and assessment of final biologic product formulations. Our subject matter expertise in the areas of Biophysics and Proteomics is showcased in over 70 peer reviewed publications.


Employees

11-50

Links